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Wen-Yi Yang, MD; Fang-Fei Wei, MD; Jan A. Staessen, MD, PhD; Tatiana Kuznetsova, MD, PhD
Background-—Population data on the longitudinal changes of left ventricular (LV) structure and function in relation to insulin
resistance are sparse. Therefore, we assessed in a general population whether hyperinsulinemia predicts longitudinal changes in
LV and arterial characteristics.
Methods and Results-—In 627 participants (mean age 50.7 years, 51.4% women), we assessed echocardiographic indexes of LV
structure and function and carotid-femoral pulse wave velocity by applanation tonometry at baseline and after 4.7 years. We
regressed longitudinal changes in these indexes on baseline insulin and its change during follow-up, and reported standardized
effect sizes as a percentage of the SD of LV changes associated with a doubling of insulin. After adjustment, higher baseline insulin
predicted a greater temporal increase in LV mass index (effect size: +15.1%) and E/e0 ratio (+22.1%), and a greater decrease in e0
peak and longitudinal strain (11.2% to 17.1%). A greater increase in insulin during follow-up related to a greater increase in LV
mass index (+10.7%) and decline in ejection fraction and longitudinal strain (11.4% to 15.7%). Participants who became or
remained insulin resistant during follow-up experienced worse changes in longitudinal strain, E/e0, and LV mass index as compared
with participants who did not develop or had improved insulin resistance over time (P≤0.033). Moreover, multivariable-adjusted
increase in pulse wave velocity was higher in participants with diabetes mellitus than in participants without diabetes mellitus
(+1.46 m/s versus +0.71 m/s; P=0.039).
Conclusions-—Hyperinsulinemia at baseline and during follow-up predicted worsening of LV function and remodeling over time.
Our ﬁndings underline the importance of management of insulin resistance. ( J Am Heart Assoc. 2018;7:e008315. DOI: 10.
1161/JAHA.117.008315.)
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D iabetes mellitus is a surging contributor to the epidemicof heart failure (HF).1 In patients with symptomatic HF,
the presence of diabetes mellitus independently increases the
risk of cardiovascular outcomes such as HF hospitalization
rates and mortality.2,3 As the process of adverse myocardial
remodeling and dysfunction starts years to decades before
the onset of HF symptoms, recent guidelines emphasized the
timely identiﬁcation and management of risk factors for HF
such as hypertension, obesity, and diabetes mellitus.4
Within this context, insulin resistance may play an
important role in the initiation and progression of metabolic
cardiomyopathy. Numerous experimental studies have already
demonstrated a cluster of disturbances in cell metabolism and
signaling induced by insulin resistance that adversely affects
left ventricular (LV) contractility and stiffness.5–7 For instance,
in the stressed state (eg, ischemia, pressure load, injury), the
impaired ability of the insulin-resistant cardiomyocytes to
switch from free fatty acid (FFA) to more effective glucose
oxidation metabolism limits the heart’s capacity for adaptive
energy response.7 The compensatory augmentation of FFA
metabolism, in turn, leads to increased oxygen consumption,
decreased cardiac efﬁciency, and lipotoxicity.8 It was also
established that metabolic disturbances triggered by hyper-
glycemia, insulin resistance, and increased FFA levels induce
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oxidative stress and chronic low-grade inﬂammation, which
leads to microvasculopathy and macrovasculopathy.9
Previous cross-sectional large-scale community-based
studies have demonstrated an independent association of
subclinical LV remodeling and dysfunction with insulin
resistance.10–15 On the other hand, population data on the
longitudinal changes of LV structure and function in relation
to insulin resistance are sparse. Serial imaging studies are
essential to elucidate the impact of insulin resistance on early
signs of LV maladaptation and arterial stiffness that forerun
symptomatic HF and other cardiovascular outcomes. There-
fore, in a general population sample, we prospectively tested
the hypothesis that hyperinsulinemia and insulin resistance
predict alterations in echocardiographic indexes of LV struc-
ture and function and arterial stiffness over time.
Methods
The data, analytic methods, and study materials will be made
available to other researchers for purposes of reproducing the
results or replicating the procedure. Because consent given by
study participants did not include data sharing with third
parties, anonymized data can be made available to investiga-
tors for analysis on reasonable request to the corresponding
author.
Study Participants
The ethics committee of the University of Leuven approved
the FLEMENGHO (Flemish Study on Environment, Genes and
Health Outcomes). From 1985 until 2005, we randomly
recruited a family-based population sample within a
geographically deﬁned area in northern Belgium as described
elsewhere.16 From 2005 to 2009, we invited 1031 former
participants for an examination including echocardiography
and applanation tonometry. We obtained written informed
consent in 828 participants (participation rate, 80.3%). We
invited these participants for a follow-up examination on
average 4.7 years (5th–95th percentile, 3.7–5.4 years) after
their ﬁrst echocardiographic examination. We excluded 147
participants because they died (n=25), were lost to follow-up
(n=19), or declined the follow-up invitation (n=103). For this
analysis, we additionally excluded 54 participants presenting
with atrial ﬁbrillation (n=12), an artiﬁcial pacemaker (n=4), or
insufﬁcient echocardiographic image quality (n=38) at base-
line and/or at follow-up. In total, we statistically analyzed 627
participants (Figure S1).
Echocardiography
Data acquisition
A detailed echocardiographic protocol is provided in Data S1.
Brieﬂy, an experienced physician (T.K.) performed both
echocardiographic examinations using a Vivid7 Pro and Vivid
E9 (GE Vingmed), respectively, interfaced with a 2.5- to 3.5-
MHz phased-array probe.16,17 With the participants in partial
left decubitus, the observer obtained images along the
parasternal long and short axes and from the apical 4- and
2-chamber and long-axis views together with a simultaneous
ECG signal.
Ofﬂine analysis
One observer (T.K.) analyzed the digitally stored echocardio-
grams blinded to the participants’ characteristics using
EchoPac software (GE Vingmed). Measurements were aver-
aged over 3 heart cycles for statistical analysis. LV internal
diameter and interventricular septal and posterior wall
thickness were measured from the 2-dimensionally guided
M-mode tracing at end-diastole. Relative wall thickness was
calculated as 0.59(interventricular septum+posterior wall)/
LV internal diameter at end-diastole. End-diastolic LV
dimensions were used to calculate LV mass. Using the
standard Simpson method, LV volumes and ejection fraction
(EF) were derived from the apical 4- and 2-chamber views.
Transmitral blood ﬂow signals were used to measure peak
early (E) and late (A) diastolic velocity and E/A ratio. From
pulsed-wave tissue Doppler imaging (TDI) recordings, we
measured the peak systolic (s0) and early diastolic (e0)
velocities of the mitral annulus at septal, lateral, inferior, and
posterior acquisition sites. E/e0 ratio was calculated by
dividing transmitral E peak by e0 averaged from the 4
acquisition sites.
As previously described,16 2 observers (T.K., N.C.) derived
LV longitudinal strain (LS) using commercially available
Clinical Perspective
What Is New?
• In this longitudinal population study, we showed that higher
levels of insulin at baseline and its increase over follow-up
were associated with the decline in left ventricular systolic
performance (by longitudinal strain and ejection fraction),
worsening of diastolic function (by E/e0), and increase in left
ventricular mass index.
What Are the Clinical Implications?
• Effective management of insulin resistance may prevent or
delay the development of adverse left ventricular remodel-
ing and dysfunction preceding metabolic cardiomyopathy
and symptomatic heart failure.
• The preventive strategies might tackle the rising contribu-
tion of (pre)diabetes mellitus to the epidemic of symp-
tomatic heart failure.
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myocardial speckle-tracking software (Q-analysis, GE
Vingmed) at default settings. The LV endocardial border
was manually traced at the end-systolic frame of the
2-dimensional 4-chamber view. The software automatically
tracked myocardial speckle motion while dividing the region
of interest in LV basal, mid, and apical levels. We adjusted the
region of interest after visual evaluation of the tracking.
Images were rejected if tracking was inadequate in ≥2
segments. We obtained basal-mid and apical LS by averaging
the segmental LS of the respective regions. We used absolute
values of peak systolic midwall LS for statistical analysis.
Detailed information on interobserver reproducibility of LS is
provided in Data S1.
Arterial Stiffness
Arterial tonometry was performed using an SPC-301 micro-
manometer (Millar Instruments Inc.) interfaced with a laptop
running SphygmoCor version 7.1 (AtCor Medical Pty Ltd).18 At
baseline and follow-up, trained observers successfully
recorded ECG-gated arterial pressure waveforms in both the
carotid and femoral arteries in 420 participants. We measured
the distance from the suprasternal notch to the carotid
sampling site and from the suprasternal notch to the femoral
sampling site. Pulse transit time was the time between the
upstroke of carotid and femoral pulse averaged for 10
consecutive beats. Aortic pulse wave velocity (PWV), the
current noninvasive gold standard of arterial stiffness,18 was
the ratio of the carotid-sternal-femoral distance (in meters) to
the pulse transit time (in seconds). Intraobserver intrasession
reproducibility was 2.61%.
Other Measurements
Conventional blood pressure was the average of 5 ausculta-
tory readings obtained with the patient in the seated position.
Hypertension was deﬁned as a blood pressure of at least
140 mm Hg systolic or 90 mm Hg diastolic and/or the use of
antihypertensive drugs. We administered a standardized
questionnaire to collect detailed information on medical
history, lifestyle, and intake of medications. Fasting venous
blood samples were drawn for measurement of biomarkers.
Baseline and follow-up serum insulin levels were measured by
an Elecsys sandwich immunoassay (Roche Diagnostics).
Diabetes mellitus was determined by self-report, a fasting
glucose level of at least 126 mg/dL, or the use of antidiabetic
agents. We calculated the Homeostatic Model Assessment of
Insulin Resistance (HOMA-IR) as the product of fasting
glucose (in mmol/L) and serum insulin (in lmol/L) divided
by 22.5. Participants whose HOMA-IR values exceeded the
75th percentile (ie, 2.62) were considered to have insulin
resistance.19
Statistical Analysis
For database management and statistical analysis, we used
SAS version 9.4 (SAS Institute). We compared means and
proportions between baseline and follow-up visits by a paired
t test and McNemar test, respectively. Signiﬁcance was
P<0.05 on 2-sided tests. We checked the distributions of all
biochemical parameters and normalized them by a logarithmic
transformation if needed.
By use of a mixed model, we assessed multivariable-
adjusted associations between longitudinal changes in
echocardiographic LV indexes and serum insulin levels while
accounting for family clusters. All models were adjusted for
baseline LV index, follow-up duration, age, sex, heart rate,
body height, body weight, pulse pressure, and mean arterial
pressure, as well as longitudinal changes in these risk
factors.20,21 Our models were also adjusted for starting,
remaining, or stopping antihypertensive treatment (per drug
class, if needed). We reported the multivariable-adjusted
regression coefﬁcients per doubling in serum insulin and its
percentage of longitudinal change on a relative scale as a
percentage of the standardized effect size (ie, the absolute
effect size divided by the SD of the echocardiographic
changes multiplied by 100). We also expressed adjusted
regression coefﬁcients for LV changes in each quartile of
HOMA-IR relative to the overall LV change in the whole study
population, which allowed quartile-speciﬁc computation of
regression coefﬁcients without deﬁnition of an arbitrary
reference group.
Next, we constructed a partial regression diagram includ-
ing multivariable-adjusted changes in LV phenotype and
serum insulin using JMP Genomics 6.0. This approach ﬁts
covariance selection models, estimating the correlation
between pairs of variables adjusted for their correlations with
all other variables in the network (ie, partial correlations). In
contrast to the 1-to-1 associations retrieved from the mixed
models, this method provides adjusted correlations while
accounting for the complex relations of the LV structural and
functional indexes with one another.
Finally, we performed forward stepwise regression to
determine clinical correlates of changes over time in PWV.
Covariables considered in stepwise regression were baseline
PWV, years of follow-up, age, sex, body mass index, heart
rate, pulse pressure, mean arterial pressure, smoking,
history of diabetes mellitus, history of coronary heart
disease, serum creatinine, total cholesterol, blood sugar,
serum insulin, HOMA-IR, and starting, remaining, or stopping
antihypertensive treatment (per drug class). We also
included longitudinal changes in these risk factors in the
stepwise models. We set the P value for variables to enter
the stepwise regression models at 0.15 and selected
variables with P<0.05.
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Results
Characteristics of Participants
At baseline, the mean age of the 627 participants (50.7%
women) was 50.614.6 years. Tables 1 and 2 present the
clinical, PWV, and echocardiographic characteristics of the
study cohort by examination phase. Of note, serum insulin
increased signiﬁcantly over time (P=0.0010), whereas fasting
blood glucose did not signiﬁcantly change (P=0.89; Table 1).
Hence, HOMA-IR also increased during follow-up (P=0.0042).
From visit 1 to 2, relative wall thickness and LV mass index
(LVMI) increased (P<0.0001) following an increase in LV wall
thicknesses (P<0.0001) and decrease in LV internal diastolic
dimensions (P=0.030; Table 2). Of LV systolic indexes, EF and
TDI s0 peak as well as 4-chamber global and apical LS
decreased signiﬁcantly over time (P≤0.034). During follow-up,
transmitral and TDI e0 and a0 as well as E/A ratio decreased
(P<0.0001), whereas E/e0 ratio increased (P<0.0001).
Tables S1 and S2 show these characteristics by sex and
examination phase.
Associations Between Changes in LV Indexes and
Serum Insulin
Table 3 shows the standardized multivariable-adjusted esti-
mates (95% conﬁdence interval) of longitudinal changes in
Table 1. Clinical Characteristics of 627 Participants at Baseline and Follow-Up Examination
Characteristic Visit 1 (2005–2009) Visit 2 (2009–2013) D P Value
Anthropometrics
Age, y 50.614.6 55.314.5 +4.720.58 <0.0001
Body mass index, kg/m² 26.44.14 27.14.19 +0.711.85 <0.0001
Waist circumference, cm 89.912.0 95.312.2 +5.367.31 <0.0001
Brachial systolic BP, mm Hg 128.616.7 132.116.8 +3.5213.5 <0.0001
Brachial diastolic BP, mm Hg 79.89.38 82.29.73 +2.458.63 <0.0001
Brachial pulse pressure, mm Hg 48.814.2 49.915.6 +1.0711.3 0.017
Mean arterial pressure, mm Hg 96.010.4 98.810.2 +2.819.08 <0.0001
Heart rate, beats per min 60.39.35 60.09.63 0.327.47 0.29
Questionnaire data, No. (%)
Current smoking 121 (19.3) 98 (15.6) 3.7% <0.0001
Drinking alcohol 259 (41.3) 239 (38.1) 3.2% 0.072
Hypertensive 259 (41.3) 316 (50.4) +9.1% <0.0001
Treated for hypertension 154 (24.6) 203 (32.4) +7.8% <0.0001
b-Blockers 94 (15) 107 (17.1) +2.1% 0.066
ACEIs or ARBs 51 (8.14) 86 (13.7) +5.6% <0.0001
CCBs or a-blockers 26 (4.20) 55 (8.80) +4.6% <0.0001
Diuretics 55 (8.77) 69 (11.0) +2.2% 0.054
History of CHD 22 (3.51) 44 (7.02) +3.5% <0.0001
History of diabetes mellitus 21 (3.35) 48 (7.66) +4.3% <0.0001
Biochemical data
Serum creatinine, lmol/L 86.115.5 89.622.8 +3.4714.1 <0.0001
Total cholesterol, mmol/L 5.270.95 5.020.95 0.250.90 <0.0001
hs-CRP, mg/L 1.50 (0.69–5.02) 1.49 (0.63–4.81) 0.001 (2.33 to 1.94) 0.99
hs-IL6, pg/mL 1.46 (0.69–3.23) 1.49 (0.70–3.47) 0.050 (1.18 to 1.37) 0.80
Blood glucose, mmol/L 4.920.73 4.910.72 0.0050.83 0.89
Serum insulin, lmol/L 4.72 (2.00–10.0) 5.13 (2.00–12.0) +1.09 (0.57 to 2.03) 0.0010
HOMA-IR 1.06 (0.13–6.94) 1.28 (0.17–10.2) +1.21 (0.23 to 6.78) 0.0042
Values are mean (SD), number of participants (percentage), or median (10–90% percentile interval). For longitudinal changes (D), values are mean (SD) or geometric mean (10–90%
percentile interval) or percentage change. ACEIs indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BP, blood pressure; CCBs, calcium channel
blockers; CHD, coronary heart disease; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; hs-CRP, high-sensitivity C-reactive protein; hs-IL6, high-sensitivity interleukin 6.
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LV indexes associated with a doubling in serum insulin at
baseline or with a doubling of the percentage increase in
serum insulin during follow-up. After adjustment, a higher
level of serum insulin at baseline predicted a greater
temporal increase in LVMI (standardized effect size:
+15.1%, P=0.0015) and decrease in 4-chamber global LS
(13.5%, P=0.0058) and basal-mid LS (17.1%, P=0.0003
[Table 3]). Moreover, the decrease in TDI e0 peak (11.2%,
P=0.040) and the increase in E/e0 ratio (+22.1%; P=0.0002)
over time were independently related to higher insulin at
baseline. In parallel, we observed that a greater increase in
insulin during follow-up was independently associated with a
greater increase in LVMI (+10.7%, P=0.023) and stronger
decline in EF (11.4%, P=0.0028), 4-chamber LS (12.6%,
P=0.0033), and basal-mid LS (15.7%, P=0.0001 [Table 3]).
In a sensitivity analysis including 606 participants free from
diabetes mellitus at baseline, these ﬁndings remained similar
(Table S3).
With exception of changes in posterior wall thickness
(+9.97%, P=0.011), none of the longitudinal changes in LV
structure and function were independently associated with
fasting blood glucose at baseline or the changes in blood
glucose during follow-up after adjustment including insulin
(P≥0.074; Table S4). Similar to our ﬁndings on insulin, higher
HOMA-IR at baseline and longitudinal increase in HOMA-IR
over time independently predicted a greater increase in LVMI
(P≤0.018) and decrease in EF and 4-chamber LS during
follow-up (P≤0.027; Table S4). Furthermore, a greater longi-
tudinal increase in E/e0 ratio was associated with a higher
baseline HOMA-IR (+8.85%, P=0.0002).
Of the systemic inﬂammatory markers, change in high-
sensitivity C-reactive protein was independently related to
Table 2. PWV and Echocardiographic Characteristics of 627 Patients at Baseline and Follow-Up Examination
Characteristic Visit 1 (2005–2009) Visit 2 (2009–2013) D P Value
PWV,* m/s 7.591.71 8.332.07 +0.741.39 <0.0001
LV structure
Internal diameter, cm 5.050.45 5.030.43 0.0260.30 0.030
Septal wall, cm 0.980.16 1.000.16 +0.0300.12 <0.0001
Posterior wall, cm 0.890.14 0.940.12 +0.0540.11 <0.0001
Relative wall thickness, cm 0.370.06 0.390.05 +0.0180.05 <0.0001
Mass index, g/m² 92.020.8 95.621.2 +3.7212.9 <0.0001
Length, cm 8.120.75 8.110.72 0.0140.52 0.50
Δ EDV, mL 99.925.6 94.725.1 4.8617.2 <0.0001
Δ ESV, mL 37.411.7 36.911.6 0.408.72 0.28
LV systolic function
Ejection fraction, % 63.56.43 61.26.43 2.338.21 <0.0001
TDI s0 peak, cm/s‡ 9.081.41 8.021.30 1.061.04 <0.0001
Global LS, %† 19.72.36 19.52.36 0.202.32 0.034
Basal-mid LS, %† 18.52.26 18.62.18 +0.102.15 0.24
Apical LS, %† 23.54.23 22.03.79 1.444.36 <0.0001
LV diastolic function
Left atrial volume index, mL/m² 23.06.06 25.86.64 +2.874.18 <0.0001
E peak, cm/s 75.916.0 67.115.7 8.8511.6 <0.0001
A peak, cm/s 64.616.9 60.115.1 3.689.15 <0.0001
E/A ratio 1.270.47 1.180.45 0.080.27 <0.0001
TDI e0 peak, cm/s‡ 11.53.56 9.813.36 1.691.56 <0.0001
TDI a0 peak, cm/s‡ 10.22.06 9.572.11 0.601.52 <0.0001
E/e0 ratio‡ 7.042.12 7.392.45 +0.351.43 <0.0001
Values are mean (SD). For longitudinal changes (D), values are mean (SD). EDV indicates end-diastolic volume; ESV, end-systolic volume; LV, left ventricular; TDI, tissue Doppler
imaging.
*Measurements of pulse wave velocity (PWV) were available at both baseline and follow-up in 420 patients.
†Longitudinal strain (LS) measured in the apical 4-chamber view.
‡Average of septal, lateral, inferior, and posterior mitral annulus sites.
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higher baseline insulin (+17.1%, P=0.0021) and change in
insulin (+16.4%, P=0.0006). Similarly, high-sensitivity inter-
leukin 6 also increased over time with higher baseline insulin
(+14.8%, P=0.011). However, the associations of changes in
LV indexes with the baseline inﬂammatory markers and their
changes over time did not reach statistical signiﬁcance after
adjustment (P≥0.078).
LV Changes in Relation to Progression of Insulin
Resistance Status
We further assessed temporal changes in LV 4-chamber LS,
E/e0 ratio, and LVMI by baseline HOMA-IR quartile (Figure 1)
and by progression of insulin resistance status during follow-
up (Figure 2 and Table S5). Compared with the averaged LV
changes in the whole cohort, participants belonging to the
fourth quartile of baseline HOMA-IR distribution (with insulin
resistance) experienced more detrimental changes in
4-chamber LS measured at basal-mid segments, E/e0 ratio,
and LVMI during follow-up (P≤0.034; Figure 1). Participants
who developed insulin resistance over time (n=97) showed a
stronger decrease in 4-chamber LS and increase in E/e0
ratio compared with those who had normal HOMA-IR
(n=374) at baseline and during follow-up (P≤0.018; Fig-
ure 2). On the other hand, participants with sustained insulin
resistance over time (n=94) exhibited worse changes in
4-chamber LS, E/e0 ratio, and LVMI as compared with
participants with normal HOMA-IR at both visits (P≤0.026;
Figure 2).
Serum Insulin Within the Network of LV Changes
Figure 3 illustrates a complex network of interactions
between the multivariable-adjusted temporal changes in
echocardiographic indexes of LV systolic and diastolic
function and LV structure. While accounting for these LV
traits interactions, the partial regression analysis conﬁrmed
the direct relation of higher insulin level at baseline with an
increase in LVMI and E/e0 during follow-up (Figure 3). Of the
LV systolic function indexes, a greater decline in 4-chamber
Table 3. Multivariable-Adjusted Associations of 4.7 Years of Changes in LV Structure and Function With Serum Insulin
Baseline Serum Insulin, Per Doubling
Δ Serum Insulin, Per Doubling of the Percentage
Increase
Parameter Estimate (95% CI) P Value Parameter Estimate (95% CI) P Value
LV structure
Δ Internal diameter, cm 0.38% (10.3 to 9.55) 0.94 0.21% (8.82 to 9.25) 0.96
Δ Septal wall, cm 3.05% (6.60 to 12.8) 0.53 5.75% (3.05 to 14.5) 0.20
Δ Posterior wall, cm 10.4% (1.90 to 18.9) 0.017 3.00% (4.69 to 10.8) 0.44
Δ Relative wall thickness 6.72% (2.90 to 16.4) 0.17 4.97% (3.79 to 13.7) 0.27
Δ Mass index, g/m² 15.1% (5.84 to 24.5) 0.0015 10.7% (1.46 to 20.0) 0.023
Δ EDV, mL 2.20% (12.6 to 8.15) 0.68 4.46% (13.9 to 4.97) 0.35
Δ ESV, mL 5.12% (5.13 to 15.4) 0.33 8.04% (1.31 to 17.4) 0.092
LV systolic function
Δ EF, % 8.44% (17.0 to 0.078) 0.052 11.4% (18.9 to 5.16) 0.0028
Δ Global LS, % 13.5% (23.1 to 3.94) 0.0058 12.6% (20.9 to 4.20) 0.0033
Δ Basal-mid LS, % 17.1% (26.2 to 7.98) 0.0003 15.7% (23.6 to 7.77) 0.0001
Δ Apical LS, % 4.72% (13.5 to 4.04) 0.29 4.83% (11.8 to 2.84) 0.22
LV diastolic function
Δ E peak, cm/s 6.78% (3.04 to 16.6) 0.18 2.02% (10.9 to 6.89) 0.66
Δ E/A 1.72% (7.80 to 11.2) 0.72 6.84% (15.4 to 2.10) 0.11
Δ TDI e0 peak, cm/s 11.2% (22.0 to 0.50) 0.040 9.34% (19.0 to 0.33) 0.058
Δ E/e0 22.1% (10.5 to 33.6) 0.0002 7.56% (2.89 to 18.0) 0.16
Parameter estimates (95% conﬁdence interval [CI]) are the changes in the left ventricular (LV) indices associated with a doubling of the baseline insulin (second column) or a doubling of the
longitudinal percentage increase in insulin (fourth column). The parameter estimates are expressed as a percentage of SD of the longitudinal change (Δ) in LV index. Analyses were
adjusted for follow-up duration, baseline LV index, age, sex, heart rate, body height, body weight, pulse pressure, and mean arterial pressure. We additionally adjusted for longitudinal
changes in these risk factors and for 3 indicator variables coding for antihypertensive drug class intake (starting or stopping treatment between baseline and follow-up and remaining on
treatment). All covariables were identiﬁed based on stepwise regression analyses. For LV mass index, models did not include anthropometric characteristics. EDV indicates end-diastolic
volume; EF, ejection fraction; ESV, end-systolic volume; LS, longitudinal strain; TDI, tissue Doppler imaging.
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basal-mid LS remained related to higher insulin level at
baseline and its change over time (Figure 3).
Partial regression analysis also conﬁrmed the direct
relation of baseline insulin and its change with high-sensitivity
C-reactive protein (Figure S2). We did not observe direct
relations between the longitudinal changes in LV indexes and
systemic inﬂammatory markers (Figure S2).
Change in PWV and History of Diabetes Mellitus
Between visits 1 and 2, PWV increased by 10.9%
(P<0.0001; Table 2). A greater longitudinal increase in
PWV was related to higher age, heart rate, and pulse
pressure at baseline (P≤0.017) and greater increase in
heart rate during follow-up (P≤0.011; Table S6). After
adjustment for these important confounders, the longitudi-
nal increase in PWV was more pronounced in participants
with a history of diabetes mellitus at baseline as compared
with those without (+1.46 m/s versus +0.71 m/s, P=0.039
[Table S6]). We did not observe any signiﬁcant association
of PWV with insulin or HOMA-IR measured at baseline or
follow-up (P≥0.089).
Discussion
In this longitudinal, community-based study, we explored the
impact of hyperinsulinemia and insulin resistance on temporal
changes in LV structure and function as assessed by echocar-
diography. The key ﬁnding of our study was that higher level of
serum insulin at baseline and its increase during follow-up
independently predicted an increase in LVMI and worsening in
LV systolic and diastolic function over time. We also observed
high interrelations of temporal changes in LV structure and
function indexes. In addition, we showed that participants with
a history of diabetes mellitus exhibited greater arterial stiffen-
ing over time than participants without diabetes mellitus.
Figure 1. Multivariable-adjusted parameter estimates (PEs; SE) for 4.7 years of change (D) in left
ventricular (LV) longitudinal strain (LS), E/e0, and LV mass index per Homeostatic Model Assessment of
Insulin Resistance (HOMA-IR) quartile. Number of participants per quartile: quartile 1, n=160; quartile 2,
n=152; quartile 3, n=159; quartile 4: n=156. Adjusted PEs are expressed as percentage of SD of the
longitudinal change in LV index. P values are for comparisons with the overall LV index changes in the whole
cohort. Analyses were adjusted for follow-up duration, baseline LV index, age, sex, heart rate, body height,
body weight, pulse pressure, and mean arterial pressure. We additionally adjusted for longitudinal changes
in these risk factors and for 3 indicator variables coding for antihypertensive drug class intake (starting or
stopping treatment between baseline and follow-up and remaining on treatment).
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Recent HF guidelines emphasized the need for better
understanding and management of risk factors triggering the
subclinical LV dysfunction that precedes HF symptoms by
years to decades.4 Indeed, the myocardium already under-
goes structural and metabolic changes in the presence of
cardiovascular risk factors years to decades before symp-
tomatic HF emerges. Within this context, insulin resistance
along with other cardiovascular factors might play an
important role in the initiation and progression of cardiac
remodeling and dysfunction.
Numerous experimental studies clariﬁed the mechanisms
of insulin resistance on LV contractility and stiffness.5–7 The
normal unstressed heart mainly relies on oxidation of FFAs for
energy production, but is able to switch to more energy-
efﬁcient glycolysis during the stressed state such as pressure
load, ischemia, or injury. Insulin resistance leads to a
decrease of the glucose uptake by cardiomyocytes and,
therefore, to a lower glycolysis rate.22,23 The heart responds
by augmenting FFA metabolism, which, in turn, leads to
increased oxygen consumption, decreased cardiac efﬁciency,
and lipotoxicity.7 In addition to a disturbance in energy
production, compensatory excess of FFA uptake dysregulates
the cellular Ca2+ handling, thereby disturbing the myocardial
excitation-contraction coupling.24 Furthermore, insulin resis-
tance is linked to sympathetic dysregulation, mitochondrial
dysfunction, increased oxidative stress, low-grade chronic
inﬂammation, and irreversible deposition of advanced glyca-
tion end-products in the coronary microvasculature.7 Impor-
tantly, the cascade of metabolic dysregulations triggered by
insulin resistance is responsible for the cardiac dysfunction
even before systemic hyperglycemia.25
So far, previous population studies have described the
relation of LV structure and function with insulin resistance in
a cross-sectional manner. For instance, 2 cross-sectional,
Figure 2. Multivariable-adjusted parameter estimates (SE) for 4.7 years of change (D) in left ventricular
(LV) longitudinal strain (LS), E/e0, and LV mass index in patients with regression, development, or
persistence of insulin resistance (IR) during follow-up. Adjusted parameter estimates (PEs) are expressed as
percentage of SD of the longitudinal change in LV index. P values are for comparisons with the reference
group, which includes patients who had normal Homeostatic Model Assessment of Insulin Resistance at
baseline and follow-up (n=374). Analyses were adjusted for follow-up duration, baseline LV index, age, sex,
heart rate, body height, body weight, pulse pressure, and mean arterial pressure. We additionally adjusted
for longitudinal changes in these risk factors and for 3 indicator variables coding for antihypertensive drug
class intake (starting or stopping treatment between baseline and follow-up and remaining on treatment).
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community-based studies demonstrated an independent
association between the degree of insulin resistance (by
HOMA-IR) and increased LVMI and LV mass to volume ratio
assessed by MRI.10,11 In addition, insulin resistance was also
associated with LV diastolic dysfunction, namely with increased
E/e0 and decreased TDI e0 velocity.12,13 Another cross-
sectional analysis in 6231 Framingham participants showed
that worse LS was, independently of other obesity-related
phenotypes, associated with higher values of HOMA-IR.14 In the
CARDIA (Coronary Artery Risk Development in Young Adults)
study (n=3179), participants belonging to the impaired glucose
tolerance group had higher relative wall thickness and lower LS
and e0 peak measured 25 years after initial examination
compared with the group with normal glucose metabolism at
baseline.15 However, the authors could not evaluate temporal
changes in LV indexes in relation to insulin resistance because
echocardiography was performed only at the ﬁnal follow-up
examination.15 Also, statistical analysis in the CARDIA study
was limited to comparisons of LV traits between different
groups of glucose metabolism.
Serial imaging studies remain essential to better understand
subclinical LV deterioration over time and to assess the role of
insulin resistance herein. Longitudinal community-based stud-
ies showed that, in parallel with adverse changes in cardiac
geometry, LV systolic and diastolic function tends to worsen
over the adult life course, particularly in the presence of risk
factors such as hypertension and diabetes mellitus.20,21,26,27 In
our longitudinal study, for the ﬁrst time, we comprehensively
assessed in both continuous and categorical analyses the
impact of insulin resistance on the natural history of LV
remodeling and dysfunction, while considering the complex
interrelations between the longitudinal LV changes. We showed
that higher levels of insulin at baseline and its increase over
follow-up were associated with the decline in LV systolic
performance (by LS and EF), worsening of diastolic function (by
E/e0), and the increase in LVMI (Figure 4).
Arterial stiffening is another consequence of diabetes
mellitus. Several studies in healthy patients and those with
Figure 3. Partial correlation diagram between 4.7 years of
change (D) in left ventricular (LV) structure and function and
insulin. The full and dashed lines represent direct and inverse
correlations, respectively (P<0.05 for all). Thicker lines imply
stronger relationships. LV changes were adjusted as explained in
the footnote to Table 3. ApLS indicates apical longitudinal strain;
BmLS, basal-mid longitudinal strain; EF, ejection fraction; GLS,
global longitudinal strain measured in the apical 4-chamber view;
Ins, insulin; LVMI, LV mass index; RWT, relative wall thickness.
Figure 4. Relation of insulin resistance to longitudinal changes in left ventricular (LV) structure and
function. In this longitudinal population study, progression of insulin resistance status during follow-up was
associated with the decline in LV systolic performance (by longitudinal strain), worsening of diastolic
function (by E/e0), and increase in LV mass index.
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diabetes mellitus found a link between higher aortic stiffness
(by PWV) and diabetes mellitus.28 For instance, the Malm€o
Diet and Cancer Study prospectively observed an independent
relation between baseline insulin resistance and PWV mea-
sured 16 years after the initial examination.29 Similar to our
ﬁndings, de Oliveira Alvim et al30 showed that over 5 years of
follow-up, PWV increased by 0.4 m/s in 355 patients without
diabetes mellitus and by 1.5 m/s in 25 patients with diabetes
mellitus. Thus, the accelerated arterial stiffening found in
patients with diabetes mellitus might be a consequence of the
activation of proinﬂammatory factors, the irreversible depo-
sition of advanced glycation end-products in the arterial wall,
and increased oxidative stress, leading to vasculopathy.28,31
Along these lines, we observed that markers of systemic
inﬂammation such as high-sensitivity C-reactive protein and
high-sensitivity interleukin 6 increased more over time with
higher baseline insulin.
Our ﬁndings suggest that insulin resistance mediates the
subclinical deterioration of LV performance besides important
cardiovascular risk factors. As such, early detection and
effective management of insulin resistance may prevent or
delay the development of subclinical LV remodeling and
dysfunction preceding metabolic cardiomyopathy and symp-
tomatic HF. These strategiesmight tackle the rising contribution
of (pre)diabetes mellitus to the epidemic of symptomatic HF.
Study Limitations
Our study has to be interpreted within the context of its
potential limitations and strengths. First, echocardiographic
measurements are prone to measurement errors as a result of
signal noise, acoustic artefacts, and angle dependency. In the
present study, an experienced observer recorded all echocar-
diographic images using a standardized imaging protocol at
baseline and follow-up. All digitally stored images were
centrally postprocessed by 2 experienced observers with
good reproducibility. Second, in our study, we did not evaluate
LV deformation in circumferential and radial direction. How-
ever, LV longitudinal strain appears to be the most robust
echocardiographic metric with independent predictive value16
as compared with circumferential and radial strain, and
therefore it might be easily implemented in clinical practice to
detect subclinical systolic dysfunction in high-risk patients.
Third, our study population included only white Europeans,
limiting the extrapolation of our ﬁndings to other ethnicities.
Conclusions
In this longitudinal population study, increased insulin resis-
tance at baseline and during follow-up predicted LV hyper-
trophy and worsening in LV systolic and diastolic function
over time. Patients with a history of diabetes mellitus
exhibited stronger arterial stiffening as compared with
participants without diabetes mellitus. Our ﬁndings under-
score the importance of management of insulin resistance in
patients at risk for cardiovascular disease.
Sources of Funding
The European Union (HEALTH-F7-305507 HOMAGE) and
European Research Council (ERC Advanced Grant-2011-
294713-EPLORE, PoC Grant 713601-uPROPHET) supported
the Studies Coordinating Centre (Leuven, Belgium). The
Studies Coordinating Centre also received grants from the
Fonds voor Wetenschappelijk Onderzoek Vlaanderen, Brus-
sels, Belgium (grants G.0880.13, G.0881.13 and 11Z0916N).
Disclosures
None.
References
1. Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, Tschoepe D,
Doehner W, Greene SJ, Senni M, Gheorghiade M, Fonarow GC. Impact of
diabetes on epidemiology, treatment, and outcomes of patients with heart
failure. JACC Heart Fail. 2015;3:136–145.
2. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC. Heart
failure prevalence, incidence, and mortality in the elderly with diabetes.
Diabetes Care. 2004;27:699–703.
3. MacDonald MR, Jhund PS, Petrie MC, Lewsey JD, Hawkins NM, Bhagra S,
Munoz N, Varyani F, Redpath A, Chalmers J, MacIntyre K, McMurray JJ.
Discordant short- and long-term outcomes associated with diabetes in
patients with heart failure: importance of age and sex: a population study of
5.1 million people in Scotland. Circ Heart Fail. 2008;1:234–241.
4. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow
GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC,
Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam
F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for
the management of heart failure: a report of the American College of
Cardiology Foundation/American Heart Association Task Force on Practice
Guidelines. J Am Coll Cardiol. 2013;62:e147–e239.
5. Ouwens DM, Boer C, Fodor M, de Galan P, Heine RJ, Maassen JA, Diamant M.
Cardiac dysfunction induced by high-fat diet is associated with altered
myocardial insulin signalling in rats. Diabetologia. 2005;48:1229–1237.
6. Velez M, Kohli S, Sabbah HN. Animal models of insulin resistance and heart
failure. Heart Fail Rev. 2014;19:1–13.
7. Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy clinical evidence,
mechanisms, and treatment options. J Am Coll Cardiol. 2008;51:93–102.
8. An D, Rodrigues B. Role of changes in cardiac metabolism in development of
diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2006;291:H1489–
H1506.
9. Nishida K, Otsu K. Inﬂammation and metabolic cardiomyopathy. Cardiovasc
Res. 2017;113:389–398.
10. Velagaleti RS, Gona P, Chuang ML, Salton CJ, Fox CS, Blease SJ, Yeon SB,
Manning WJ, O’Donnell CJ. Relations of insulin resistance and glycemic
abnormalities to cardiovascular magnetic resonance measures of cardiac
structure and function: the Framingham Heart Study. Circ Cardiovasc Imaging.
2010;3:257–263.
11. Shah RV, Abbasi SA, Heydari B, Rickers C, Jacobs DR Jr, Wang L, Kwong RY,
Bluemke DA, Lima JA, Jerosch-Herold M. Insulin resistance, subclinical left
ventricular remodeling, and the obesity paradox: MESA (Multi-Ethnic Study of
Atherosclerosis). J Am Coll Cardiol. 2013;61:1698–1706.
12. Demmer RT, Allison MA, Cai J, Kaplan RC, Desai AA, Hurwitz BE, Newman JC,
Shah SJ, Swett K, Talavera GA, Thai A, Youngblood ME, Rodriguez CJ.
Association of impaired glucose regulation and insulin resistance with cardiac
DOI: 10.1161/JAHA.117.008315 Journal of the American Heart Association 10
Left Ventricular Changes and Insulin Resistance Cauwenberghs et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on A
pril 5, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
structure and function: results from ECHO-SOL (Echocardiographic Study of
Latinos). Circ Cardiovasc Imaging. 2016;9:e005032.
13. Fontes-Carvalho R, Ladeiras-Lopes R, Bettencourt P, Leite-Moreira A, Azevedo
A. Diastolic dysfunction in the diabetic continuum: association with insulin
resistance, metabolic syndrome and type 2 diabetes. Cardiovasc Diabetol.
2015;14:4.
14. Ho JE, McCabe EL, Wang TJ, Larson MG, Levy D, Tsao C, Aragam J, Mitchell GF,
Benjamin EJ, Vasan RS, Cheng S. Cardiometabolic traits and systolic
mechanics in the community. Circ Heart Fail. 2017;10:e003536.
15. Kishi S, Gidding SS, Reis JP, Colangelo LA, Venkatesh BA, Armstrong AC,
Isogawa A, Lewis CE, Wu C, Jacobs DR Jr, Liu K, Lima JA. Association of insulin
resistance and glycemic metabolic abnormalities with LV structure and
function in middle age: the CARDIA study. JACC Cardiovasc Imaging.
2017;10:105–114.
16. Kuznetsova T, Cauwenberghs N, Knez J, Yang WY, Herbots L, D’hooge J,
Haddad F, Thijs L, Voigt JU, Staessen JA. Additive prognostic value of left
ventricular systolic dysfunction in a population-based cohort. Circ Cardiovasc
Imaging. 2016;9:e004661.
17. Lang RM, Badano LP, Mor-Avi V, Aﬁlalo J, Armstrong A, Ernande L,
Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru
D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU.
Recommendations for cardiac chamber quantiﬁcation by echocardiography in
adults: an update from the American Society of Echocardiography and the
European Association of Cardiovascular Imaging. J Am Soc Echocardiogr.
2015;28:1–39.e14.
18. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D,
Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H. Expert consensus
document on arterial stiffness: methodological issues and clinical applications.
Eur Heart J. 2006;27:2588–2605.
19. Balkau B, Charles MA. Comment on the provisional report from the WHO
consultation. European Group for the Study of Insulin Resistance (EGIR).
Diabet Med. 1999;16:442–443.
20. Cauwenberghs N, Knez J, D’hooge J, Thijs L, Yang WY, Wei FF, Zhang ZY,
Staessen JA, Kuznetsova T. Longitudinal changes in LV structure and diastolic
function in relation to arterial properties in general population. JACC
Cardiovasc Imaging. 2017;10:1307–1316.
21. Kuznetsova T, Thijs L, Knez J, Cauwenberghs N, Petit T, Gu YM, Zhang Z,
Staessen JA. Longitudinal changes in left ventricular diastolic function in a
general population. Circ Cardiovasc Imaging. 2015;8:e002882.
22. Szablewski L. Glucose transporters in healthy heart and in cardiac disease. Int
J Cardiol. 2017;230:70–75.
23. Gibbs EM, Stock JL, McCoid SC, Stukenbrok HA, Pessin JE, Stevenson RW,
Milici AJ, McNeish JD. Glycemic improvement in diabetic db/db mice by
overexpression of the human insulin-regulatable glucose transporter (GLUT4).
J Clin Invest. 1995;95:1512–1518.
24. Lebeche D, Davidoff AJ, Hajjar RJ. Interplay between impaired calcium
regulation and insulin signaling abnormalities in diabetic cardiomyopathy. Nat
Clin Pract Cardiovasc Med. 2008;5:715–724.
25. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ, Cooksey
RC, Litwin SE, Abel ED. Reduced cardiac efﬁciency and altered substrate
metabolism precedes the onset of hyperglycemia and contractile dysfunction
in two mouse models of insulin resistance and obesity. Endocrinology.
2005;146:5341–5349.
26. Lieb W, Xanthakis V, Sullivan LM, Aragam J, Pencina MJ, Larson MG, Benjamin
EJ, Vasan RS. Longitudinal tracking of left ventricular mass over the adult life
course: clinical correlates of short- and long-term change in the Framingham
Offspring Study. Circulation. 2009;119:3085–3092.
27. Lieb W, Xanthakis V, Sullivan LM, Aragam J, Pencina MJ, Larson MG, Benjamin
EJ, Vasan RS. The natural history of left ventricular geometry in the
community: clinical correlates and prognostic signiﬁcance of change in LV
geometric pattern. JACC Cardiovasc Imaging. 2014;7:870–878.
28. Prenner SB, Chirinos JA. Arterial stiffness in diabetes mellitus. Atherosclerosis.
2015;238:370–379.
29. Gottsater M, Ostling G, Persson M, Engstrom G, Melander O, Nilsson PM. Non-
hemodynamic predictors of arterial stiffness after 17 years of follow-up: the
Malmo Diet and Cancer study. J Hypertens. 2015;33:957–965.
30. de Oliveira Alvim R, Santos PC, Musso MM, de Sa Cunha R, Krieger JE, Mill JG,
Pereira AC. Impact of diabetes mellitus on arterial stiffness in a representative
sample of an urban Brazilian population. Diabetol Metab Syndr. 2013;5:45.
31. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes
mellitus: insights from mechanistic studies. Lancet. 2008;371:1800–1809.
DOI: 10.1161/JAHA.117.008315 Journal of the American Heart Association 11
Left Ventricular Changes and Insulin Resistance Cauwenberghs et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on A
pril 5, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
  
 
 
SUPPLEMENTAL MATERIAL 
 
 by guest on A
pril 5, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Data S1. 
Supplemental Methods 
 
ECHOCARDIOGRAPHY   
The participants refrained from smoking, heavy exercise and drinking alcohol or caffeine-
containing beverages for at least 3 hours prior to the examination. To ensure steady state, 
echocardiography and arterial measurements were obtained consecutively and after the subjects 
had rested for at least 15 min in the supine position. 
Data acquisition. One experienced physician (T.K.) did both echocardiographic examinations 
using a Vivid7 Pro and Vivid E9 (GE Vingmed, Horten, Norway), respectively, interfaced with a 
2.5- to 3.5-MHz phased-array probe. The observer obtained M-mode recordings of the LV from 
the parasternal long axis view guided by the 2D image. The ultrasound beam was positioned just 
below the mitral valve at the level of the posterior chordae tendineae. Gray-scale images were 
obtained from the parasternal long and short axes and from the apical 4- and 2-chamber and 
long-axis views. From the apical window, the observer positioned a 1- to 3-mm Doppler sample 
volume at the mitral valve tips to record pulsed wave Doppler transmitral flow velocities. The 
sonographer placed a 5-mm tissue Doppler sample at septal, lateral, inferior and posterior sites of 
the mitral annulus to record mitral annular velocity patterns. All digitally stored recordings included 
at least 5 cardiac cycles.  
Off-line analysis. One observer (T.K.) analyzed the echocardiograms blinded to the participants’ 
characteristics using EchoPac software, version BT13 (GE Vingmed, Horten, Norway). All 
measurements were averaged over three heart cycles for statistical analysis. LV internal diameter 
and interventricular septal and posterior wall thickness were measured from the 2D-guided M-
mode tracing at end-diastole. Relative wall thickness (RWT) was calculated as 
0.5x(interventricular septum + posterior wall) / LV internal diameter at end-diastole. LV 
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dimensions were used to calculate LV mass via an anatomically validated formula. Left atrial (LA) 
volume was calculated by the prolate-ellipsoid method from LA dimensions measured in the 
parasternal long, lateral and supero-inferior axes. LA volume and LV mass was indexed to body 
surface area (BSA), calculated as body weight0.425 (in kg) x body height0.725 (in cm) x 0.007184. 
Using the standard Simpson method, LV end-diastolic volume (EDV), end-systolic volume (ESV) 
and ejection fraction (EF) were derived from the apical 4- and 2 chamber views. Transmitral blood 
flow signals were used to measure peak early (E) and late (A) diastolic velocity. From the Tissue 
Doppler Imaging (TDI) recordings, we measured the peak systolic (s’) and early diastolic (e’) 
velocities of the mitral annulus at septal, lateral, inferior and posterior acquisition sites. E/e’ ratio 
was calculated by dividing transmitral E peak by e’ averaged from the 4 acquisition sites.  
2D LV strain. Two observers (T.K. and N.C.) derived LV longitudinal strain (LS) using a 
myocardial speckle-tracking software package (Q-analysis, GE Vingmed) at default settings. The 
LV endocardial border was manually traced at the end-systolic frame of the 2D apical 4-chamber 
view. The software automatically tracked myocardial speckle motion while dividing the region of 
interest in LV basal, mid and apical levels. We adjusted the region of interest to the myocardial 
thickness and further adjustments were made after visual evaluation of the tracking. Images were 
rejected when tracking was inadequate in ≥2 segments. We obtained basal-mid and apical LS by 
averaging the segmental LS of the respective regions. We used absolute values of peak systolic 
midwall LS for statistical analysis.  
Reproducibility 
The data on intra-observer reproducibility was published elsewhere [see ref 16]. To further assess 
the inter-observer reproducibility for assessment of LS, two experienced observers (T.K. and 
N.C.) measured in duplicates LV 4-chamber LS in 53 subjects. The reproducibility was estimated, 
using the Bland-Altman plots. The absolute bias was calculated as the difference between the 
observers’ measurements (x2 – x1) and was plotted against their average ((x2 + x1) / 2 = average 
x). The relative bias was calculated as the difference between paired readings, divided by the 
average (((x1 – x2) / average x)*100) and was plotted against the average value of repeated 
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readings (average x). For the inter-observer (T.K. and N.C.) variability, the mean absolute and 
relative differences between pairwise readings for 4-chamber LS were 0.040±1.38% and 
0.25±7.23% respectively.  
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Table S1. Clinical Characteristics of Men and Women at Baseline and Follow-up Examination. 
 Men (n = 305)  Women (n = 322) 
Characteristic 
Visit 1 
(2005-2009) 
Visit 2                      
(2009-2013) 
P value  Visit 1 
(2005-2009) 
Visit 2                      
(2009-2013) 
P value 
Anthropometrics        
Age, y 50.3 ± 14.7 55.0 ± 14.6 <0.0001  50.8 ± 14.5 55.5 ± 14.4 <0.0001 
Body mass index, kg/m² 26.6 ± 3.45 27.4 ± 3.59 <0.0001  26.2 ± 4.70 26.8 ± 4.67 <0.0001 
Waist circumference, cm 94.2 ± 9.78 98.7 ± 10.3 <0.0001  85.9 ± 12.5 92.1 ± 13.1 <0.0001 
Brachial systolic BP, mm Hg 130.0 ± 14.5 132.6 ± 15.0 0.0002  127.2 ± 18.5 131.6 ± 18.4 <0.0001 
Brachial diastolic BP, mm Hg 81.9 ± 9.27 83.7 ± 9.55 0.0003  77.8 ± 9.06 80.8 ± 9.70 <0.0001 
Brachial pulse pressure, mm Hg 48.1 ± 12.4 48.9 ± 14.2 0.18  49.4 ± 15.6 50.7 ± 16.7 0.050 
Mean arterial pressure, mm Hg 97.9 ± 9.6 100.0 ± 9.5 <0.0001  94.2 ± 10.7 97.7 ± 10.7 <0.0001 
Heart rate, bpm 58.4 ± 9.09 58.1 ± 9.17 0.48  62.2 ± 9.24 61.8 ± 9.72 0.42 
Questionnaire data        
Current smoking, n (%) 64 (21.0) 50 (16.4) 0.0005  57 (17.7) 48 (14.9) 0.012 
Drinking alcohol, n (%) 185 (60.7) 168 (55.1) 0.046  74 (23.0) 71 (22.0) 0.77 
Hypertensive, n (%) 138 (45.2) 166 (54.4) 0.0005  121 (37.6) 150 (46.6) <0.0001 
Treated for hypertension, n (%) 73 (23.9) 103 (33.8) <0.0001  81 (25.2) 100 (31.1) 0.0003 
   β-blockers, n (%) 46 (15.1) 55 (18.0) 0.093  48 (14.9) 52 (16.1) 0.50 
   ACE or ARB, n (%) 26 (8.52) 41 (13.4) 0.0059  25 (7.76) 45 (14.0) <0.0001 
   CCB or α-blockers, n (%) 14 (4.59) 35 (11.5) 0.0002  12 (3.73) 20 (6.21) 0.039 
   Diuretics, n (%) 19 (6.23) 31 (10.2) 0.017  36 (11.2) 38 (11.8) 0.84 
History of CHD, n (%) 16 (5.25) 35 (11.5) <0.0001  6 (1.86) 9 (2.80) 0.25 
History of diabetes, n (%) 10 (3.28) 23 (7.54) 0.0002  11 (3.42) 25 (7.76) 0.0001 
Biochemical data    
    
Serum creatinine, µmol/L 93.9 ± 15.3 98.3 ± 25.7 <0.0001  78.6 ± 11.6 81.3 ± 15.8 <0.0001 
Total cholesterol, mmol/L 5.13 ± 0.94 4.83 ± 0.89 <0.0001  5.41 ± 0.95 5.20 ± 0.97 <0.0001 
hs-CRP, mg/L 1.23 (0.51-2.85) 1.37 (0.69 -3.65) 0.24  1.81 (0.76-7.42) 1.62 (0.74 -5.60) 0.059 
hs-IL6, pg/mL 1.37 (0.68-3.04) 1.48 (0.69 -3.54) 0.21  1.55 (0.59-3.59) 1.49 (0.62-3.43) 0.48 
Blood glucose, mmol/L 5.02 ± 0.85 4.99 ± 0.68 0.57  4.81 ± 0.59 4.84 ± 0.75 0.65 
Serum insulin, µmol/L 4.66 (2.00-9.00) 5.15 (2.30-12.0) 0.0054  4.79 (2.00-11.0) 5.12 (2.00-12.0) 0.074 
HOMA-IR 1.07 (0.13-6.77) 1.35 (0.19-10.4) 0.016  1.04 (0.14-9.07) 1.22 (0.15-7.70) 0.096 
Values are mean (±SD), number of subjects (%) or geometric mean (10-90% percentile interval). ACE indicates angiotensin-converting enzyme; ARB, angiotensin 
receptor blockers; BP, blood pressure; bpm, beats per minute; CCB, calcium channel blockers and CHD, coronary heart disease; HOMA-IR, Homeostatic Model 
Assessment of Insulin Resistance; hs-CRP, high-sensitivity C-reactive protein; hs-IL6, high-sensitivity interleukin-6.
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Table S2. PWV and Echocardiographic Characteristics of Men and Women at Baseline and Follow-up 
Examination. 
 Men (n = 305)  Women (n = 322) 
Characteristic 
Visit 1 
(2005-2009) 
Visit 2                      
(2009-2013) 
P value  Visit 1 
(2005-2009) 
Visit 2                      
(2009-2013) 
P value 
Pulse wave velocity, m/s 7.59 ± 1.71 8.33 ± 2.07* <0.0001  7.30 ± 1.75 7.94 ± 2.09* <0.0001 
LV structure        
Internal diameter, cm 5.26 ± 0.42 5.23 ± 0.40 0.082  4.85 ± 0.37 4.83 ± 0.35 0.18 
Septal wall, cm 1.04 ± 0.15 1.07 ± 0.14 0.0001  0.91 ± 0.14 0.94 ± 0.14 <0.0001 
Posterior wall, cm 0.95 ± 0.13 1.00 ± 0.11 <0.0001  0.84 ± 0.13 0.89 ± 0.11 <0.0001 
Relative wall thickness, cm 0.38 ± 0.06 0.40 ± 0.06 <0.0001  0.36 ± 0.06 0.38 ± 0.05 <0.0001 
Mass index, g/m² 100.3 ± 20.0 103.4 ± 20.2 <0.0001  84.1 ± 18.5 88.3 ± 19.4 <0.0001 
Length, cm 8.58 ± 0.66 8.51 ± 0.63 0.051  7.69 ± 0.56 7.72 ± 0.58 0.21 
      EDV, ml 115.5 ± 22.7 110.0 ± 22.6 0.0002  84.4 ± 17.6 79.9 ± 17.2 <0.0001 
      ESV, ml 43.9 ± 11.0 43.7 ± 10.8 0.79  30.9 ± 8.27 30.3 ± 7.75 0.019 
LV systolic function        
Ejection fraction, % 62.8 ± 6.39 60.2 ± 6.22 <0.0001  64.2 ± 6.40 62.1 ± 6.49 <0.0001 
TDI s’ peak, cm/s# 9.51 ± 1.35 8.29 ± 1.25 <0.0001  8.67 ± 1.34 7.77 ± 1.29 <0.0001 
Global LS, % 18.9 ± 2.22 18.7 ± 2.16 0.032  20.4 ± 2.27 20.3 ± 2.27 0.38 
Basal-mid LS, % 17.9 ± 2.15 17.8 ± 2.04 0.83  19.1 ± 2.20 19.3 ± 2.06 0.071 
Apical LS, % 22.6 ± 4.21 21.2 ± 3.39 <0.0001  24.3 ± 4.08 22.9 ± 3.96 <0.0001 
LV diastolic function        
      LA volume index, ml/m² 24.0 ± 5.94 27.0 ± 6.29 <0.0001  22.0 ± 6.03 24.7 ± 6.78 <0.0001 
E peak, cm/s 71.8 ± 15.3 62.9 ± 14.4 <0.0001  79.8 ± 15.7 71.1 ± 15.9 <0.0001 
A peak, cm/s 61.0 ± 16.2 57.5 ± 14.2 <0.0001  68.0 ± 16.9 64.2 ± 15.3 <0.0001 
E/A ratio 1.28 ± 0.50 1.17 ± 0.44 <0.0001  1.25 ± 0.43 1.19 ± 0.47 <0.0001 
TDI e’ peak, cm/s# 11.5 ± 3.56 9.66 ± 3.25 <0.0001  11.5 ± 3.44 9.96 ± 3.46 <0.0001 
TDI a’ peak, cm/s# 10.5 ± 2.09 9.80 ± 2.11 <0.0001  9.89 ± 1.99 9.34 ± 2.09 <0.0001 
E/e’ ratio# 6.63 ± 1.88 6.96 ± 2.00 <0.0001  7.43 ± 2.27 7.80 ± 2.75 <0.0001 
Values are mean (±SD). *Follow-up measurements of pulse wave velocity were available in 420 subjects.  #Average of septal, lateral, inferior and posterior mitral 
annulus sites. 2D indicates two-dimensional; EDV, end-diastolic volume; ESV, end-systolic volume; LA, left atrium; LS, longitudinal strain; LV, left ventricle; TDI, 
tissue Doppler imaging. 
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Table S3. Multivariable-adjusted Associations of 4.7 Years Change in LV Structure and 
Function with Serum Insulin in 606 Subjects Free of Diabetes Mellitus at Baseline. 
Parameter estimates (95% CI) are the changes in the LV indices associated with a doubling of the baseline 
insulin (second column) or a doubling of the longitudinal percentage increase in insulin (fourth column). The 
parameter estimates are expressed as a percentage of SD of the longitudinal change in LV index. Analyses were 
adjusted for follow-up duration, baseline LV index, age, sex, heart rate, body height, body weight, pulse pressure 
and mean arterial pressure. We additionally adjusted for longitudinal changes in these risk factors and for 3 
indicator variables coding for antihypertensive drug class intake (starting or stopping treatment between baseline 
and follow-up and remaining on treatment). All covariables were identified based on stepwise regression 
analyses. For LV mass index, models did not include anthropometric characteristics. EDV indicates end-diastolic 
volume; ESV, end-systolic volume; LS, longitudinal strain; LV, left ventricular; TDI, Tissue Doppler Imaging.    
 
Baseline serum insulin, per doubling ∆ Serum insulin, per doubling of the 
percentage increase 
 
Parameter estimate             
(95% CI) 
P value Parameter estimate           
(95% CI) 
P value 
LV structure     
  ∆ Internal diameter, cm -5.70% (-16.3, 4.92) 0.30 -4.86% (-14.7, 4.97) 0.33 
  ∆ Septal wall, cm  3.66% (-6.83, 14.1) 0.49 7.01% (-2.72, 16.7) 0.16 
  ∆ Posterior wall, cm  10.4% (1.18, 19.6) 0.027 4.21% (-1.18, 12.7) 0.33 
  ∆ Relative wall thickness 8.87% (-1.58, 19.3) 0.096 7.27% (-2.41, 17.0) 0.14 
  ∆ Mass index, g/m² 12.7% (2.85, 22.5) 0.012 8.58% (-1.48, 18.6) 0.094 
  ∆ EDV, ml -8.43% (-20.0, 3.13) 0.15 -11.2% (-21.9, -0.54) 0.040 
  ∆ ESV, ml 2.73% (-8.69, 14.1) 0.64 6.47% (-4.12, 17.1) 0.23 
LV systolic function     
  ∆ Ejection fraction, % -9.00% (-18.5, 0.52) 0.064 -13.2% (-21.9, -4.50) 0.0030 
  ∆ Global LS, % -13.4% (-23.7, -3.03) 0.011 -14.7% (-24.2, -5.15) 0.0026 
  ∆ Basal-mid LS, % -15.9% (-25.8, -5.87) 0.0019 -15.3% (-24.5, -6.24) 0.0010 
  ∆ Apical LS, % -3.48% (-12.9, 5.91) 0.47 -5.27% (-13.7, 3.11) 0.22 
LV diastolic function     
  ∆ E peak, cm/s 7.63% (-2.68, 17.9) 0.15 -3.59% (-13.1, 5.87) 0.46 
  ∆ E/A  2.53% (-7.75, 12.8) 0.63 -9.29% (-18.8, 0.21) 0.055 
  ∆ TDI e’ peak, cm/s -12.0% (-23.1, -0.90) 0.034 -14.3% (-24.5, -4.14) 0.0059 
  ∆ E/e’ 25.2% (13.1, 37.3) <0.0001 11.0 (-0.21, 22.1) 0.055 
 by guest on A
pril 5, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Table S4. Multivariable-adjusted Associations of 4.7 Years Change in LV Structure and Function with Blood Glucose and HOMA-IR.  
 Blood glucose HOMA-IR 
 
Baseline, +0.73 mmol/L ∆, +0.83 mmol/L Baseline, per doubling ∆, per doubling of the 
percentage increase 
 
Parameter estimate             
(95% CI) 
P value Parameter estimate             
(95% CI) 
P value Parameter estimate             
(95% CI) 
P value Parameter estimate             
(95% CI) 
P value 
LV structure         
  ∆ Internal diameter, cm -1.40% (-10.4, 7.62) 0.76 -1.99% (-10.8, 6.82) 0.65 0.15% (-3.58, 4.24) 0.94 0.10% (-3.58, 3.77) 0.96 
  ∆ Septal wall, cm 5.53% (-3.16, 14.2) 0.21 2.83% (-5.69, 11.4) 0.51  1.13% (-2.83, 5.09) 0.57 2.34% (-1.22, 5.89) 0.20 
  ∆ Posterior wall, cm 9.97% (2.29, 17.7) 0.011 1.96% (-5.58, 9.49) 0.61 5.15% (1.66, 8.65) 0.0039 1.74% (-1.41, 4.88) 0.28 
  ∆ RWT 6.38% (-2.35, 15.1) 0.15 3.63% (-4.93, 12.2) 0.41 2.64% (-1.32, 6.60) 0.19 2.12% (-1.43, 5.68) 0.24 
  ∆ Mass index, g/m² 6.46% (-3.38, 16.3) 0.20 1.69% (-7.91, 11.3) 0.73 6.53% (2.71, 10.4) 0.0009 4.50% (0.78, 8.23) 0.018 
  ∆ EDV, ml 4.37% (-4.66, 13.4) 0.34 -1.35% (-7.50, 10.2) 0.77 -1.07% (-5.41, 3.27) 0.63 -2.05% (-5.93, 1.82) 0.30 
  ∆ ESV, ml 3.54% (-5.36, 12.4) 0.43 6.49% (-2.20, 15.2) 0.14 2.67% (-1.54, 6.90) 0.21 3.90% (0.085, 7.71) 0.045 
LV systolic function         
  ∆ Ejection fraction, % -3.68% (-11.6, 4.25) 0.36 -5.42% (-13.2, -2.35) 0.17 -4.09% (-7.71, -0.48) 0.027 -5.03% (-8.24, -1.82) 0.0022 
  ∆ Global LS, % -7.30% (-16.0, 1.44) 0.10 -7.80% (-16.4, 0.77) 0.074 -6.12% (-10.1, -2.15) 0.0026 -5.72% (-9.26, 2.18) 0.0016 
  ∆ Basal-mid LS, % -6.52% (-15.1, 2.03) 0.13 -4.56% (-13.0, 3.84) 0.29 -7.24% (-11.1, -3.35) 0.0003 -6.21% (-9.66, -2.74) 0.0005 
  ∆ Apical LS, % -4.62% (-12.7, 3.51) 0.27 -7.09% (-15.1, 0.89) 0.081 -2.27% (-5.92, 1.38) 0.22 -2.46% (-5.62, 0.71) 0.13 
LV diastolic function         
  ∆ E peak, cm/s 0.31% (-8.68, 9.29) 0.95 1.14% (-7.63, 9.90) 0.80 3.09% (-0.98, 7.15)  0.14 -0.69% (-4.33, 2.95) 0.71 
  ∆ E/A -2.83% (-11.5, 5.81) 0.52 0.92% (-7.56, 9.38) 0.83 0.72 % (-3.20, 4.65) 0.71 -2.47% (-5.98, 1.05) 0.17 
  ∆ TDI e’ peak, cm/s -7.03% (-16.2, 2.18) 0.13 -1.43% (-10.4, 7.59) 0.76 -4.52% (-8.77, -0.28) 0.037 -3.78% (-7.56, -0.02) 0.049 
  ∆ E/e’ 2.24% (-8.01, 12.5) 0.67 2.34% (-7.66, 12.4) 0.65 8.85% (-4.19, 13.5) 0.0002 3.25% (-0.92, 7.43) 0.13 
Parameter estimates (95% CI) are the changes in the LV indices associated with a 1-SD in baseline glucose or its change over time and with doubling of the baseline HOMA-IR or a doubling of the 
longitudinal percentage increase in HOMA-IR. Parameter estimates (95% CI) are expressed as percentage of SD of the longitudinal change in LV index. Analyses were adjusted for follow-up duration, 
baseline LV index, age, sex, heart rate, body height, body weight, pulse pressure and mean arterial pressure. We additionally adjusted for longitudinal changes in these risk factors and in 
antihypertensive treatment. Blood glucose was additionally adjusted for insulin levels. All covariables were identified based on stepwise regression analyses. For LV mass index, models did not include 
anthropometric characteristics. EDV indicates end-diastolic volume; ESV, end-systolic volume; HOMA-IR, homeostatic model assessment of insulin resistance; LS, longitudinal strain; LV, left 
ventricular; TDI, Tissue Doppler Imaging; RWT, relative wall thickness.
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Figure S5. Clinical and Echocardiographic Characteristics of Participants by Insulin 
Resistance Group at Baseline and Follow-up Examination. 
Characteristic 
Normal HOMA-IR  
(n=374; 59.7%)  
Regressed IR  
(n=62; 9.89%) 
Developed IR 
(n=97; 15.5%) 
Sustained IR 
(n=94; 14.9%) 
P for trend 
Clinical 
characteristics 
  
  
 
  Female (%) 193 (51.6%) 36 (58.1%) 50 (51.5%) 43 (45.7%) 0.51 
  Age, y      
    Baseline 49.7 ± 14.1 44.6 ± 15.6 53.5 ± 15.8 54.9 ± 12.7 <0.0001 
    Follow-up 54.5 ± 14.0 49.3 ± 15.7 58.0 ± 15.8 59.4 ± 12.7 <0.0001 
    Δ +4.81 ± 0.51 +4.73 ± 0.72 +4.56 ± 0.63 +4.55 ± 0.59 <0.0001 
  Body weight, kg      
    Baseline 71.8 ± 13.0 78.1 ± 13.4 78.3 ± 11.1 86.7 ± 16.4 <0.0001 
    Follow-up 73.6 ± 13.3 78.8 ± 13.2 82.7 ± 13.0 88.0 ± 15.5 <0.0001 
    Δ +1.84 ± 4.48 +0.65 ± 6.21 +4.32 ± 5.16 +1.25 ± 7.57 <0.0001 
  PP, mm Hg      
    Baseline 47.6 ± 13.7 48.4 ± 13.3 51.8 ± 15.8 50.8 ± 14.3 0.028 
    Follow-up 48.8 ± 15.2 46.3 ± 13.8 52.4 ± 14.9 54.0 ± 17.7 0.0025 
    Δ +1.21 ± 11.4 -2.15 ± 10.2  +0.60 ± 11.3 +3.16 ± 10.9 0.036 
  MAP, mm Hg      
    Baseline 94.8 ± 9.75 94.9 ± 11.4 96.9 ± 9.99 100.9 ± 11.0 <0.0001 
    Follow-up 97.8 ± 10.0 97.3 ± 8.94 101.2 ± 10.3 101.7 ± 100.5 0.0002 
    Δ +2.98 ± 9.09 +2.40 ± 8.66 +4.33 ± 8.89 +0.78 ± 9.27 0.058 
  Heart rate, bpm      
    Baseline 59.0 ± 8.92 63.7 ± 9.70 60.3 ± 8.58 63.3 ± 10.4 <0.0001 
    Follow-up 58.5 ± 8.92 61.9 ± 9.15 62.1 ± 9.96 62.5 ± 11.2 <0.0001 
    Δ -0.46 ± 7.24 -1.86 ± 7.65 +1.76 ± 7.43 -0.87 ± 8.00 0.012 
LV structure      
  RWT      
    Baseline 0.37 ± 0.059 0.36 ± 0.056 0.37 ± 0.059 0.40 ± 0.066 0.0007 
    Follow-up 0.38 ± 0.052 0.38 ± 0.052 0.40 ± 0.062 0.41 ± 0.049 <0.0001 
    Δ 0.015 ± 0.051 +0.024 ± 0.042 +0.026 ± 0.056 +0.016 ± 0.058 0.30 
  Mass index, g/m²      
    Baseline 90.4 ± 19.3 90.3 ± 23.0 93.5 ± 24.9 97.6 ± 20.0 0.0055 
    Follow-up 93.2 ± 19.4 94.6 ± 23.2 98.0 ± 24.5 103.3 ± 21.2 <0.0001 
    Δ 2.78 ± 11.6 +4.31 ± 14.1 +5.11 ± 14.3 +5.65 ± 15.0 0.016 
LV systolic function      
  EF, %      
    Baseline 63.3 ± 6.29 63.0 ± 5.80 63.8 ± 6.28 64.4 ± 7.43 0.85 
    Follow-up 61.6 ± 6.34 61.2 ± 5.55 60.4 ± 6.25 60.5 ± 7.38 0.035 
    Δ -1.74 ± 8.03 +1.83 ± 6.88 -3.30 ± 7.99 -3.96 ± 9.62 0.14 
  Global LS, %      
    Baseline 19.9 ± 2.21 19.7 ± 2.67 19.6 ± 2.49 18.9 ± 2.47 0.0014 
    Follow-up 19.8 ± 2.26 19.5 ± 2.36 19.0 ± 2.45 18.9 ± 2.48 0.0003 
    Δ -0.12 ± 2.28 -0.12 ± 2.38 -0.67 ± 2.22 -0.047 ± 2.49 0.17 
  Basal-mid LS, %      
    Baseline 18.8 ± 2.08 18.4 ± 2.58 18.5 ± 2.53 17.5 ± 2.18 <0.0001 
    Follow-up 19.0 ± 2.00 18.6 ± 2.30 18.2 ± 2.21 17.5 ± 2.35 <0.0001 
    Δ +0.22 ± 2.10 +0.16 ± 2.04 -0.31 ± 2.33 +0.014 ± 2.23 0.0001 
  Apical LS, %      
    Baseline 23.8 ± 4.27 23.4 ± 4.55 23.1 ± 4.00 23.0 ± 4.06 0.27 
    Follow-up 22.2 ± 3.79 21.9 ± 3.87 21.4 ± 3.58 22.2 ± 3.97 0.25 
    Δ -1.55 ± 4.32 -1.47 ± 4.95 -1.64 ± 4.22 -0.78 ± 4.24 0.39 
LV diastolic function      
  E peak, cm/s      
    Baseline 77.8 ± 15.7 76.0 ± 15.9 72.3 ± 16.6 72.0 ± 15.8 0.0037 
    Follow-up 68.0 ± 14.8 70.5 ± 15.5 63.1 ± 17.2 65.2 ± 17.0 0.016 
    Δ -9.84 ± 11.5 -5.49 ± 9.90 -9.27 ± 10.3 -6.73 ± 13.4 0.042 
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  e’ peak, cm/s      
    Baseline 12.2 ± 3.44 12.2 ± 3.83 10.3 ± 3.63 9.36 ± 2.43 <0.0001 
    Follow-up 10.4 ± 3.15 10.9 ± 3.63 8.45 ± 3.44 7.95 ± 2.77 <0.0001 
    Δ -1.80 ± 1.54 -1.33 ± 1.54 -1.76 ± 1.64 -1.40 ± 1.56 0.032 
  E/e’ ratio      
    Baseline 6.72 ± 1.95 6.62 ± 1.80 7.57 ± 2.38 8.03 ± 2.28 <0.0001 
    Follow-up 6.91 ± 1.98 6.96 ± 1.97 8.14 ± 3.07 8.79 ± 2.98 <0.0001 
    Δ +0.19 ± 1.21 +0.34 ± 1.26 +0.57 ± 1.67 +0.76 ± 1.91 0.0002 
Values are mean (±SD) or number of subjects (%). EF indicates ejection fraction; HOMA-IR, homeostatic model assessment of 
insulin resistance; IR, insulin resistance; LS, longitudinal strain; MAP, mean arterial pressure; PP, pulse pressure; LV, left 
ventricle; RWT, relative wall thickness.
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Table S6. Correlates of 4.7 Years Change in Pulse Wave Velocity 
in a Subset of 420 Participants. 
 ∆ Pulse wave velocity (m/s)* 
 β ± SE R2 (%) P value 
∆, mean (5-95% CI) 0.74 
(-1.00 to 3.10) 
21.9  
Partial regression coefficients  
Years of follow-up, +1 year 0.27 ± 0.11 0.94 0.011 
Baseline risk factors     
     Baseline PWV, +2 m/s -0.71 ± 0.088 7.83 < 0.0001 
Age, +10 years  0.32 ± 0.052 5.28 <0.0001 
Heart rate, +10 bpm 0.18 ± 0.075 0.79 0.017 
Pulse pressure, +15 mm Hg 0.47 ± 0.079 5.40 <0.0001 
History of diabetes mellitus 0.73 ± 0.31 1.46 0.020 
Change in risk factors    
∆ Heart rate, +10 bpm 0.23±0.089 0.45 0.011 
We performed forward stepwise multiple regression to assess the independent 
correlations between 4.7 year change in pulse wave velocity and baseline risk 
factors such as sex, age, body mass index, heart rate, pulse pressure, mean 
arterial pressure, smoking, history of diabetes mellitus, history of coronary heart 
disease, serum creatinine, total cholesterol, blood glucose, serum insulin, HOMA-
IR, and starting, remaining or stopping with antihypertensive treatment per drug 
class. We also included longitudinal changes in these risk factors in the stepwise 
models. We set the P values for variables to enter the regression models at 0.15 
and selected the variables with a P value below 0.05. Values are mutually 
adjusted partial regression coefficients (β) ± standard error (SE). *Both baseline 
and follow-up measurements of PWV were available in 420 subjects. PWV 
indicates pulse wave velocity; R², additional variance explained by partial 
regression coefficient.
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Figure S1. Flow Chart for Participants in the FLEMENGHO Study. Flow diagram shows 
the progress through the two phases of the longitudinal population study. FLEMENGHO 
indicates Flemish Study on Environment, Genes and Health Outcomes.  
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Figure S2. Partial Correlation Diagram between 4.7 Years Change (Δ) in LV Structure 
and Function, Inflammatory Markers and Serum Insulin. The full and dashed lines 
represent direct and inverse correlations, respectively (P<0.05 for all). Thicker lines imply 
stronger relationships. LV changes were adjusted as explained in a footnote to Table 3. 
ApLS indicates apical longitudinal strain; BmLS, basal-mid longitudinal strain; EF, ejection 
fraction; GLS, global longitudinal strain; hs-CRP, high-sensitivity C-reactive protein; hs-IL6, 
high-sensitivity interleukin 6; Ins, insulin; LV, left ventricular; LVMI, LV mass index; RWT, 
relative wall thickness. 
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